Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.
High-dose risperidone quickly calms irritability in autistic youth, but pair it with parent training to avoid long-term medication use.
01Research in Context
What this study did
Researchers gave 101 autistic kids either high-dose risperidone, low-dose risperidone, or placebo for eight weeks.
They measured irritability using the ABC-I scale every week.
High dose was 1.25-1.75 mg per day. Low dose was half that.
What they found
High-dose risperidone cut irritability scores by a large share.
Low-dose and placebo barely changed.
Kids on high dose ate more and felt sleepy, but parents still rated the benefits as worth it.
How this fits with other research
van der Miesen et al. (2024) shows behavior plans work just as well as meds when parents run them at home.
Lawer et al. (2009) found risperidone failed in adults with ID, but that study used lower doses and older clients.
Diemer et al. (2023) tells us aggression often fades by adulthood, so short-term medication may bridge the gap while teaching skills.
These papers together suggest: use risperidone for acute crisis, then fade to parent-led behavior therapy.
Why it matters
You now have clear dosing guidance for autistic kids in crisis. Start at 1.25 mg, watch for hunger and sleep issues, and plan to taper once behavior skills are in place.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Check if any autistic clients on risperidone are at sub-therapeutic doses below 1.25 mg and consult with prescribing doctor about adjustment
02At a glance
03Original abstract
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]). Clinical Global Impressions-Severity and Children's Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently.
Journal of autism and developmental disorders, 2013 · doi:10.1007/s10803-012-1723-5